Avecho Biotechnology Limited (AVEFF)
USD 0.0
(157.14%)
USD 0.0
(157.14%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.24 Million AUD | -95.13% |
| 2022 | -2.1 Million AUD | 24.09% |
| 2021 | -2.97 Million AUD | -42.34% |
| 2020 | -2.09 Million AUD | -226.55% |
| 2019 | 1.54 Million AUD | 137.21% |
| 2018 | -4.59 Million AUD | 50.83% |
| 2017 | -9.03 Million AUD | -284.35% |
| 2016 | -9.55 Million AUD | 21.89% |
| 2015 | -10.84 Million AUD | 67.0% |
| 2014 | -8.91 Million AUD | 36.12% |
| 2013 | -14.05 Million AUD | -29.21% |
| 2012 | -10.8 Million AUD | -4.21% |
| 2011 | -11.31 Million AUD | -346.92% |
| 2010 | -4.81 Million AUD | 149.99% |
| 2009 | -8.93 Million AUD | -109.1% |
| 2008 | -9.95 Million AUD | 909.01% |
| 2007 | -11.67 Million AUD | -35.82% |
| 2006 | -8.59 Million AUD | -125.95% |
| 2005 | -7.7 Million AUD | -118.92% |
| 2004 | -1.73 Million AUD | -133.56% |
| 2003 | -743.77 Thousand AUD | -262.82% |
| 2002 | -998.7 Thousand AUD | -111.81% |
| 2001 | -1.04 Million AUD | 178.87% |
| 2000 | -2.2 Million AUD | -318.54% |
| 1999 | 1 Million AUD | 113.04% |
| 1998 | -7.72 Million AUD | 83.25% |
| 1997 | -46.1 Million AUD | -585.24% |
| 1996 | -6.72 Million AUD | -117.54% |
| 1995 | 38.36 Million AUD | 3629.35% |
| 1994 | -1.08 Million AUD | -146.69% |
| 1993 | 2.32 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.04 Million AUD | 0.0% |
| 2024 Q1 | -1.04 Million AUD | -70.75% |
| 2023 Q2 | -2.41 Million AUD | -139.97% |
| 2023 Q3 | -613.45 Thousand AUD | 74.63% |
| 2023 Q4 | -1.99 Million AUD | -224.73% |
| 2023 Q1 | -1 Million AUD | 46.38% |
| 2023 FY | - AUD | -95.13% |
| 2022 FY | - AUD | 24.09% |
| 2022 Q3 | -728.98 Thousand AUD | 23.59% |
| 2022 Q1 | -323.85 Thousand AUD | 85.14% |
| 2022 Q2 | -954.06 Thousand AUD | -194.59% |
| 2022 Q4 | -1.87 Million AUD | -157.82% |
| 2021 Q2 | -1.94 Million AUD | -160.11% |
| 2021 Q1 | -747.12 Thousand AUD | 55.14% |
| 2021 Q4 | -2.17 Million AUD | -193.77% |
| 2021 FY | - AUD | -42.34% |
| 2021 Q3 | -741.64 Thousand AUD | 61.84% |
| 2020 Q4 | -1.66 Million AUD | -208.49% |
| 2020 FY | - AUD | -226.55% |
| 2020 Q2 | -1.18 Million AUD | -98.08% |
| 2020 Q1 | -598.43 Thousand AUD | 47.03% |
| 2020 Q3 | -539.87 Thousand AUD | 54.46% |
| 2019 Q3 | -631.82 Thousand AUD | -126.32% |
| 2019 Q4 | -1.12 Million AUD | -78.82% |
| 2019 Q2 | 2.4 Million AUD | 101.52% |
| 2019 FY | - AUD | 137.21% |
| 2019 Q1 | 1.19 Million AUD | 220.78% |
| 2018 Q2 | -1.13 Million AUD | 0.0% |
| 2018 Q4 | -986.3 Thousand AUD | 0.0% |
| 2018 Q3 | -986.3 Thousand AUD | 13.4% |
| 2018 FY | - AUD | 50.83% |
| 2018 Q1 | -1.13 Million AUD | 0.0% |
| 2017 Q2 | -2.17 Million AUD | 0.0% |
| 2017 Q1 | -2.17 Million AUD | 4.77% |
| 2017 FY | - AUD | -284.35% |
| 2016 Q1 | -2.49 Million AUD | 17.19% |
| 2016 Q3 | -2.28 Million AUD | 8.43% |
| 2016 Q2 | -2.49 Million AUD | 0.0% |
| 2016 Q4 | -2.28 Million AUD | 0.0% |
| 2016 FY | - AUD | 21.89% |
| 2015 Q4 | -3.01 Million AUD | 0.0% |
| 2015 FY | - AUD | 67.0% |
| 2015 Q1 | -2.41 Million AUD | 7.15% |
| 2015 Q2 | -2.41 Million AUD | 0.0% |
| 2015 Q3 | -3.01 Million AUD | -24.99% |
| 2014 Q1 | -1.79 Million AUD | -14.43% |
| 2014 FY | - AUD | 36.12% |
| 2014 Q4 | -2.59 Million AUD | 0.0% |
| 2014 Q3 | -2.59 Million AUD | -44.5% |
| 2014 Q2 | -1.79 Million AUD | 0.0% |
| 2013 Q3 | -3.57 Million AUD | -11.83% |
| 2013 FY | - AUD | -29.21% |
| 2013 Q4 | -1.57 Million AUD | 56.05% |
| 2013 Q2 | -3.19 Million AUD | 0.0% |
| 2013 Q1 | -3.19 Million AUD | 0.0% |
| 2012 FY | - AUD | -4.21% |
| 2011 FY | - AUD | -346.92% |
| 2010 FY | - AUD | 149.99% |
| 2009 FY | - AUD | -109.1% |
| 2008 FY | - AUD | 909.01% |
| 2007 FY | - AUD | -35.82% |
| 2006 FY | - AUD | -125.95% |
| 2005 FY | - AUD | -118.92% |
| 2004 FY | - AUD | -133.56% |
| 2003 FY | - AUD | -262.82% |
| 2002 FY | - AUD | -111.81% |
| 2001 FY | - AUD | 178.87% |
| 2000 FY | - AUD | -318.54% |
| 1999 FY | - AUD | 113.04% |
| 1998 FY | - AUD | 83.25% |
| 1997 FY | - AUD | -585.24% |
| 1996 FY | - AUD | -117.54% |
| 1995 FY | - AUD | 3629.35% |
| 1994 FY | - AUD | -146.69% |
| 1993 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Evofem Biosciences, Inc. | -17.37 Million USD | 81.333% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 16.523% |
| CSL Limited | 4.78 Billion USD | 100.068% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 103.448% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -246.071% |
| BioStem Technologies, Inc. | -7.55 Million USD | 57.074% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -85.286% |
| Qrons Inc. | -40.08 Thousand USD | -7989.893% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 714.772% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 94.141% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 54.722% |
| Skye Bioscience, Inc. | -13.54 Million USD | 76.066% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -782.986% |
| Rebus Holdings, Inc. | -951 Thousand USD | -240.958% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 79.568% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.696% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -412.726% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 95.435% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 45.31% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1255.848% |
| SQZ Biotechnologies Company | -64.14 Million USD | 94.945% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -22.616% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -111.094% |
| Mesoblast Limited | -62.38 Million USD | 94.803% |
| Marizyme, Inc. | -34.28 Million USD | 90.542% |
| Genus plc | 73.7 Million USD | 104.4% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 50.957% |
| Pharming Group N.V. | 9.87 Million USD | 132.829% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -117.997% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 8.584% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 63.036% |
| ContraFect Corporation | -64.99 Million USD | 95.011% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 28.361% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -131.309% |
| IMV Inc. | -35.52 Million USD | 90.872% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -39.534% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -525.912% |
| ONE Bio Corp. | 13.61 Million USD | 123.819% |
| Accustem Sciences Inc. | -3.74 Million USD | 13.45% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 93.277% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -155.894% |
| Q BioMed Inc. | -617.62 Thousand USD | -424.994% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 190.776% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -41.936% |
| Biomind Labs Inc. | -1.03 Million USD | -213.423% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 91.819% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -12.107% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 48322.933% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -12870.04% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -29.599% |
| GB Sciences, Inc. | -1.41 Million USD | -128.364% |
| Alpha Cognition Inc. | -9.7 Million USD | 66.591% |
| HST Global, Inc. | -5303.00 USD | -61044.824% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -57.633% |
| Halberd Corporation | -74.27 Thousand USD | -4265.312% |
| Enzolytics Inc. | -2.12 Million USD | -52.802% |
| Agentix Corp. | -1.37 Million USD | -136.377% |
| Resverlogix Corp. | -11.74 Million USD | 72.385% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -5.86% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 98.499% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 366.435% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 136.623% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -116.325% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 955.896% |
| AVAX Technologies, Inc. | -6.11 Million USD | 46.954% |
| Zenith Capital Corp. | -8.6 Million USD | 62.323% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -18512.651% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -32.539% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1742.08% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -68.801% |
| Kadimastem Ltd | -2.62 Million USD | -23.553% |
| Helix BioMedix, Inc. | -1.04 Million USD | -209.899% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1690.571% |
| LadRx Corporation | 412.28 Thousand USD | 886.477% |
| Cell Source, Inc. | -4.27 Million USD | 24.108% |
| Regen BioPharma, Inc. | 1.46 Million USD | 321.187% |
| NovAccess Global Inc. | -1.03 Million USD | -213.347% |
| Affymax, Inc. | -14.29 Million USD | 77.317% |
| Itoco Inc. | -1.86 Million USD | -73.489% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -754.146% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -190.547% |
| Mobile Lads Corp. | -2.24 Million USD | -44.68% |
| CytoDyn Inc. | -18.02 Million USD | 82.015% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -4002.937% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -26414.924% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -567.625% |
| SYBLEU INC | -141.57 Thousand USD | -2190.377% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -205.318% |
| International Stem Cell Corporation | 202 Thousand USD | 1705.203% |
| Bioxytran, Inc. | -3.82 Million USD | 15.121% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -6059.783% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -31.706% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 90.96% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -7105.578% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -18.426% |
| Neutra Corp. | -181.24 Thousand USD | -1689.001% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 83.915% |
| PureTech Health plc | -11.62 Million USD | 72.112% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 83.914% |
| IXICO plc | -707 Thousand USD | -358.629% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 57.807% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 93.293% |
| CSL Limited | 4.73 Billion USD | 100.069% |
| Cellectis S.A. | -92.63 Million USD | 96.5% |